Heat-Sensitive Moxibustion Eases Chronic Back Pain and Reshapes the Brain-Gut-Immune Axis, Study Finds

Chronic nonspecific low back pain is one of the most stubborn and widespread health problems on the planet. According to the Global Burden of Disease Study 2021, low back pain remains the leading cause of years lived with disability worldwide, affecting more than 600 million people, with a global point prevalence of roughly 7.5 percent. For the 85 to 90 percent of sufferers whose pain has no identifiable structural cause, treatment options are frustratingly limited, and a new study from China now suggests that an ancient therapy, upgraded with a modern mechanistic lens, may act on the brain, the gut, and the immune system all at once.

Researchers at the Affiliated Hospital of Jiangnan University in Wuxi enrolled 204 patients with chronic nonspecific low back pain in a single-arm, before-and-after exploratory study, publishing their results in Frontiers in Integrative Neuroscience. Each participant received twenty sessions of heat-sensitive moxibustion, or HSM, over four consecutive weeks, five sessions per week. Unlike conventional moxibustion, which applies burning moxa at fixed acupoints, HSM begins with a scanning procedure: a lit moxa stick is hovered about three centimeters above the lumbosacral skin while the practitioner searches for so-called heat-sensitized points, where patients report striking non-local sensations such as penetrating heat, spreading warmth, or warmth traveling to distant body regions. The single most strongly sensitized point, most often Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), or an Ashi point, was then treated for 30 to 45 minutes per session, continuing until the propagated heat sensation faded.

The clinical results were dramatic. Average pain on the 10-point Visual Analog Scale fell from 5.87 at baseline to 2.21 after treatment, a mean reduction of 3.66 points with a Cohen’s d effect size of 2.71, far exceeding the 1.5-to-2.0-point threshold conventionally considered clinically important in chronic pain research. The Oswestry Disability Index, which quantifies how much back pain limits daily life, dropped from 33.86 to 18.42, and standardized depression and anxiety scores also fell significantly. Using the benchmark of at least a 50 percent pain reduction recommended by the IMMPACT initiative, 117 of the 186 completers, or 62.9 percent, qualified as treatment responders, a rate that matches or exceeds the 40-to-60 percent response rates typically reported in acupuncture trials for the same condition. Attrition was modest at 8.8 percent, and safety was reassuring: the 28 adverse events recorded in 24 patients, mostly mild redness, small blisters, transient dizziness, or itching, were all self-limiting and resolved within one to three days without intervention.

What elevates this study beyond a simple efficacy report is its simultaneous tracking of nine serum biomarkers spanning four dimensions of the brain-gut-immune axis, the bidirectional communication network linking the central nervous system, the intestinal barrier, and the immune system through neural, endocrine, and immune signaling. After false-discovery-rate correction, eight of the nine markers changed significantly. In the neuroendocrine dimension, beta-endorphin, the body’s principal endogenous opioid and the main ligand at mu-opioid receptors, rose substantially, while cortisol, the hormonal output of the stress-responsive hypothalamic-pituitary-adrenal axis, fell. In the intestinal barrier dimension, both lipopolysaccharide, the gram-negative bacterial endotoxin used as a surrogate for gut leakiness, and D-lactate, a bacterial fermentation product reflecting mucosal damage, declined markedly.

The immune-inflammatory dimension told a coherent story as well. Pro-inflammatory cytokines interleukin-6 and tumor necrosis factor-alpha decreased, high-sensitivity C-reactive protein dropped from 4.72 to 2.53 milligrams per liter, and the anti-inflammatory cytokine interleukin-10 rose. The authors propose that this rebalancing may be driven partly by vagally mediated activation of the cholinergic anti-inflammatory pathway, in which thermal afferent input from heat-sensitized acupoints engages vagal reflexes that release acetylcholine onto alpha-7 nicotinic receptors on macrophages, suppressing NF-kappa-B-dependent cytokine production. Because IL-6 and TNF-alpha sensitize peripheral nociceptors and promote spinal glial activation that sustains central sensitization, damping them down could translate directly into less pain. Consistent with that idea, changes in IL-6 correlated significantly with changes in both pain intensity and disability scores.

The neuroendocrine findings tie into classical pain neuroscience. Beta-endorphin released from the hypothalamic arcuate nucleus drives descending pain inhibition through projections to the periaqueductal gray and rostral ventromedial medulla, and landmark experiments since the 1970s have shown that acupuncture analgesia can be partially reversed by the opioid antagonist naloxone, though the authors caution that direct naloxone evidence specific to moxibustion remains limited. In this cohort, the greater a patient’s rise in beta-endorphin, the greater their pain reduction, with a correlation of r = -0.45. Meanwhile, the parallel fall in cortisol may matter beyond stress physiology: chronic glucocorticoid exposure potentiates spinal nociceptive transmission, impairs hippocampal neurogenesis involved in pain memory, and, crucially, disrupts intestinal tight-junction proteins, increasing gut permeability. Cortisol normalization may therefore act as an upstream hinge connecting the neuroendocrine, intestinal, and immune arms of the axis.

That gut connection is where the study becomes particularly provocative. A proposed gut-disc axis holds that LPS leaking across a damaged intestinal barrier enters the circulation, binds Toll-like receptor 4 on innate immune cells, and triggers low-grade inflammation that may even accelerate intervertebral disc degeneration. Supporting evidence for gut-driven pain outside the viscera is accumulating rapidly: recent work showed that transplanting fecal microbiota from fibromyalgia patients into germ-free mice produces mechanical allodynia and thermal hyperalgesia, and Mendelian randomization analyses of tens of thousands of participants have linked specific gut microbial taxa and metabolites, including serotonin, to low back pain risk. In the present study, changes in LPS correlated positively with changes in IL-6, TNF-alpha, and pain scores, and exploratory mediation analysis suggested that shifts in beta-endorphin, IL-6, hs-CRP, LPS, and cortisol partially mediated the link between treatment dose and pain improvement, with beta-endorphin accounting for the largest mediated share at 44.9 percent.

Not every biomarker behaved as predicted. Serum serotonin, or 5-hydroxytryptamine, showed only a numerical increase that failed to reach significance after correction for multiple comparisons. The authors acknowledge that serum 5-HT largely reflects platelet serotonin stores rather than free gut-derived signaling, since platelets sequester roughly 95 percent of circulating serotonin, making it a noisy surrogate. Interestingly, serotonin changes correlated weakly with improvements in depression scores but not with pain intensity, hinting that serotonergic modulation, when it occurs, may engage the affective-motivational side of pain rather than its sensory-discriminative dimension. Individual variability was also striking: 79.6 percent of patients showed beta-endorphin increases, but only 58.1 percent showed serotonin increases, suggesting subgroup-dependent effects that larger studies may disentangle.

Perhaps the most clinically actionable finding came from the prediction modeling. A multivariable logistic regression retained three independent predictors of treatment response: the mean heat-sensitization intensity score across sessions, baseline pain severity, and baseline serum LPS. The model achieved an area under the curve of 0.828, with a bootstrap-corrected value of 0.806, and sensitivity and specificity both near 77 to 78 percent. Heat-sensitization intensity, graded on a four-point scale from no sensitization to strong distant heat transmission, was the strongest predictor, echoing prior EEG evidence that heat-sensitization responses have distinct cortical signatures and parallels with temporal summation measures used to predict acupuncture response. The LPS finding is especially novel: patients with more baseline barrier disruption had more room for the gut-restoration pathway to work, and if replicated, baseline LPS could serve as a stratification biomarker for enrichment designs in future trials and for personalized treatment selection in the clinic.

The authors are careful, appropriately, about what this study cannot show. Because there was no control group, no sham moxibustion, and no blinding, the findings establish association and biological plausibility rather than causal efficacy, and expectation effects on subjective outcomes cannot be excluded, although non-responders still showed significant changes in several objective biomarkers. There was no follow-up assessment to gauge durability, no fecal microbiome sequencing to characterize microbial mediation, and serum LPS and D-lactate remain indirect measures of intestinal permeability validated mainly in surgical and gastroenterological cohorts. Still, the image that emerges is compelling: a four-week course of targeted heat therapy was accompanied by a coordinated, four-dimensional recalibration of the brain-gut-immune axis, spanning endogenous opioid activation, intestinal barrier restoration, serotonergic regulation, and immune rebalancing, in patients whose pain had resisted explanation and often resisted treatment. Whether that coordination reflects a true causal chain or an accompanying epiphenomenon will be the question for the randomized, sham-controlled trial the authors say must come next. If the answer holds, one of humanity’s oldest therapies may find its mechanism written in the language of modern systems biology, and the humble gut may take its place alongside the spine in the story of chronic back pain.

Subject of Research: Heat-sensitive moxibustion for chronic nonspecific low back pain and its putative analgesic mechanism via the brain-gut-immune axis

Article Title: Clinical efficacy and putative analgesic mechanism of heat-sensitive moxibustion for chronic nonspecific low back pain: a single-arm before-after study based on the brain-gut-immune axis

Article References: Xie, Y., & Li, C. (2026). Clinical efficacy and putative analgesic mechanism of heat-sensitive moxibustion for chronic nonspecific low back pain: a single-arm before-after study based on the brain-gut-immune axis. Frontiers in Integrative Neuroscience, 20, Article 1894020. https://doi.org/10.3389/fnint.2026.1894020

Image Credits: AI Generated

DOI: 10.3389/fnint.2026.1894020

Keywords: chronic low back pain, heat-sensitive moxibustion, brain-gut-immune axis, beta-endorphin, cortisol, lipopolysaccharide, intestinal permeability, interleukin-6, serotonin, inflammation, acupoint heat sensitization, pain biomarkers